Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors

被引:0
|
作者
Kawaguchi, Yoshiaki [1 ]
Maruno, Atsuko [1 ]
Kawashima, Yohei [1 ]
Ito, Hiroyuki [1 ]
Ogawa, Masami [1 ]
Mine, Tetsuya [1 ]
机构
[1] Tokai Univ, Dept Gastroenterol, Sch Med, Isehara, Kanagawa 2591193, Japan
关键词
Amenorrhea; Everolimus; Neuroendocrine tumor; Pancreas; Adverse event; TUBEROUS SCLEROSIS COMPLEX; CELL CARCINOMA; DOUBLE-BLIND; EFFICACY; TRIAL; MULTICENTER; OCTREOTIDE; RAPAMYCIN;
D O I
10.3748/wjg.v20.i42.15920
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The patient was an asymptomatic 43-year-old woman. Abdominal ultrasonography and enhanced computed tomography showed a tumor lesion accompanied by multiple cystic changes in the liver and the pancreatic tail. Endoscopic ultrasound-fine needle aspiration was performed on the pancreatic tumor lesion and revealed pancreatic neuroendocrine tumor (PNET). As it was unresectable due to multiple liver metastases, the decision was made to initiate treatment with everolimus and transcatheter arterial chemoembolization. The patient ceased menstruating after the start of everolimus administration. When the administration was discontinued due to interstitial lung disease, menstruation resumed, but then again stopped with everolimus resumption. An association between everolimus and amenorrhea was highly suspected. Amenorrhea occurred as a rare adverse event of everolimus. As the younger women might be included in PNETs patients, we should put this adverse event into consideration. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:15920 / 15924
页数:5
相关论文
共 50 条
  • [31] Pharmacist-Led Development of an Adverse Event (AE) Management Algorithm for the Proactive Monitoring of Patients With Neuroendocrine Tumors (NETs) on Everolimus
    Thawer, Alia
    Chan, David
    Leake, Joanna
    Dias, Samantha
    Singh, Simron
    PANCREAS, 2018, 47 (03) : 355 - 356
  • [33] Everolimus-induced Symmetrical Drug-related Intertriginous and Flexural Exanthema
    Kim, Emily Y.
    Awh, Katherine C.
    Larocca, Cecilia A.
    ACTA DERMATO-VENEREOLOGICA, 2023, 103
  • [34] MicroRNA Associated With Outcome in Pancreatic Neuroendocrine Tumors
    Gonzalez-Berjon, Jose
    Tetzlaff, Michael
    Yao, James
    Loose, David
    Broaddus, Russell
    Estrella, Jeannelyn
    MODERN PATHOLOGY, 2015, 28 : 442A - 443A
  • [35] Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
    Zhang, Lin
    Mao, Wei
    Liu, Dan
    Hu, Bin
    Lin, Xiaofang
    Ran, Jie
    Li, Xingxing
    Hu, Jing
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [36] The quality of adverse event reporting in drug-related hemorrhagic stroke trials from the stroke trials registry
    Hussein, Haitham M.
    Baybutt, Trevor R.
    Zhou, Jingying
    Divani, Afshin A.
    Qureshi, Adnan I.
    STROKE, 2007, 38 (02) : 543 - 543
  • [37] Drug-Related Keratitis: A Real-World FDA Adverse Event Reporting System Database Study
    Wu, Shi-Nan
    Chen, Xiao-Dong
    Zhang, Qing-He
    Wang, Yu-Qian
    Yan, Dan
    Xu, Chang-Sheng
    Wang, Shao-Pan
    Zhu, Linfangzi
    Qin, Dan-Yi
    Guo, Shu-Jia
    Chen, Lin
    Liu, Yu-Wen
    Huang, Caihong
    Hu, Jiaoyue
    Liu, Zuguo
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2024, 13 (09):
  • [38] Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors
    Fan, Zhiyao
    Gong, Yitao
    Huang, Qiuyi
    Yang, Chao
    Cheng, He
    Jin, Kaizhou
    Fan, Kun
    Ni, Quanxing
    Yu, Xianjun
    Luo, Guopei
    Liu, Chen
    PANCREAS, 2020, 49 (06) : 751 - 756
  • [39] MicroRNA Associated With Outcome in Pancreatic Neuroendocrine Tumors
    Gonzalez-Berjon, Jose
    Tetzlaff, Michael
    Yao, James
    Loose, David
    Broaddus, Russell
    Estrella, Jeannelyn
    LABORATORY INVESTIGATION, 2015, 95 : 442A - 443A
  • [40] When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors? Reply
    Yao, James C.
    Voi, Maurizio
    Lincy, Jeremie
    Pavel, Marianne
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) : 1488 - +